Correlation Between ADMA Biologics and Corvus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both ADMA Biologics and Corvus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ADMA Biologics and Corvus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ADMA Biologics and Corvus Pharmaceuticals, you can compare the effects of market volatilities on ADMA Biologics and Corvus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ADMA Biologics with a short position of Corvus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of ADMA Biologics and Corvus Pharmaceuticals.

Diversification Opportunities for ADMA Biologics and Corvus Pharmaceuticals

0.18

Correlation Coefficient

ADMA Biologics  Corvus Pharmaceuticals

Average diversification

The 3 months correlation between ADMA and Corvus is 0.18. Overlapping area represents the amount of risk that can be diversified away by holding ADMA Biologics and Corvus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corvus Pharmaceuticals and ADMA Biologics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ADMA Biologics are associated (or correlated) with Corvus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corvus Pharmaceuticals has no effect on the direction of ADMA Biologics i.e., ADMA Biologics and Corvus Pharmaceuticals go up and down completely randomly.

Pair Corralation between ADMA Biologics and Corvus Pharmaceuticals

Given the investment horizon of 90 days ADMA Biologics is expected to under-perform the Corvus Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, ADMA Biologics is 1.43 times less risky than Corvus Pharmaceuticals. The stock trades about -0.01 of its potential returns per unit of risk. The Corvus Pharmaceuticals is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  518.00  in Corvus Pharmaceuticals on September 24, 2024 and sell it today you would lose (57.50) from holding Corvus Pharmaceuticals or give up 11.1% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

ADMA Biologics  vs.  Corvus Pharmaceuticals

ADMA Biologics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ADMA Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong primary indicators, ADMA Biologics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Corvus Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Weak

Over the last 90 days Corvus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Corvus Pharmaceuticals is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with ADMA Biologics and Corvus Pharmaceuticals

The main advantage of trading using opposite ADMA Biologics and Corvus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ADMA Biologics position performs unexpectedly, Corvus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corvus Pharmaceuticals will offset losses from the drop in Corvus Pharmaceuticals' long position.

The idea behind ADMA Biologics and Corvus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.